Zevra Therapeutics, Inc.
$10.78
▼
-0.11%
2026-04-21 10:27:00
www.zevra.com
NMS: ZVRA
Explore Zevra Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$601.51 M
Current Price
$10.78
52W High / Low
$13.16 / $6.85
Stock P/E
7.23
Book Value
$2.72
Dividend Yield
—
ROCE
-1.72%
ROE
85.66%
Face Value
—
EPS
$1.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
61
Beta
0.89
Debt / Equity
40.87
Current Ratio
5.68
Quick Ratio
5.63
Forward P/E
6.23
Price / Sales
5.22
Enterprise Value
$428.19 M
EV / EBITDA
-2,392.14
EV / Revenue
4.02
Rating
None
Target Price
$22.78
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
| 2. | Prothena Corporation plc | $10.79 | — | $583.55 M | — | -64.54% | -63.62% | $11.69 / $4.32 | $5.21 |
| 3. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 4. | Seres Therapeutics, Inc. | $8.94 | 15.05 | $85.7 M | — | -79.05% | 19.64% | $29.98 / $6.53 | $4.63 |
| 5. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 6. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 7. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 34.12 M | 26.06 M | 25.88 M | 20.4 M | 12.04 M | — |
| Operating Profit | 9.31 M | 4.14 M | -12.33 M | -5.36 M | -15.42 M | — |
| Net Profit | 12.16 M | -0.54 M | 74.71 M | -3.1 M | -35.74 M | — |
| EPS in Rs | 0.21 | -0.01 | 1.27 | -0.05 | -0.61 | -0.69 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 106.47 M | 23.61 M | 27.46 M | 10.16 M |
| Operating Profit | -4.23 M | -87 M | -49.6 M | -24.9 M |
| Net Profit | 83.23 M | -105.51 M | -46.05 M | -26.77 M |
| EPS in Rs | 1.42 | -1.8 | -0.78 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 284.73 M | 178.13 M | 172.33 M | 115.34 M |
| Total Liabilities | 130.07 M | 138.46 M | 110.46 M | 40.22 M |
| Equity | 154.66 M | 39.67 M | 61.86 M | 75.12 M |
| Current Assets | 223.01 M | 86.03 M | 86.94 M | 92.83 M |
| Current Liabilities | 39.28 M | 34.06 M | 73.72 M | 12.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.6 M | -69.67 M | -33.53 M | -18.72 M |
| Investing CF | 18.13 M | -22.16 M | -17.39 M | -36.72 M |
| Financing CF | 12.06 M | 82.11 M | 28.46 M | 8.35 M |
| Free CF | -2.43 M | -69.67 M | -33.83 M | -18.81 M |
| Capex | -0.83 M | — | -0.3 M | -0.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -14.02% | 170.26% | — | — |
| Earnings Growth % | -129.13% | -72% | — | — |
| Profit Margin % | -446.85% | -167.69% | -263.48% | — |
| Operating Margin % | -368.47% | -180.63% | -245.07% | — |
| Gross Margin % | 68.59% | 92.09% | 97.82% | — |
| EBITDA Margin % | -323.56% | -158.56% | -251.22% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.